Skip to main content
| News

EvokAI to acquire Advancience

30.05.2022

EvokAI Creative Labs Inc. has agreed a deal to acquire Advancience. The diagnosis profiles enhanced by Artificial Intelligence (AI) developed by Advancience can be used to help monitor cognitive alterations with the aid of computer games. This should make it easier to diagnose neurodegenerative diseases such as Alzheimer’s at an early stage.

EvokAI Creative Labs is taking over Advancience AG as part of a deal announced by the AI-powered medtech firm. Both companies are based in Allschwil in the canton of Basel-Landschaft.

EvokAI is building a platform for brain health and recovery. “Our concept is aimed at measuring the invisible”, comments Alejandro Antalich, co-founder of EvokAI, in the press release. “It is also tremendously important to be able to spot arising problems as soon as possible; knowing what’s typical is the most important foundation to know if something is out of the ordinary”, he adds.

The acquisition of Advancience brings the company one step closer to bridging the gap between neuroscience and AI. As part of EvokAI’s expansion plan, the takeover of Advancience will enable it to combat Alzheimer’s.

Advancience participated in DayOne Accelerator

Advancience is working with the University of Basel. The company offers digital, fully automated tests, in which it integrates gaming elements. By simulating various scenarios, these can be regarded as a “perfect tool to probe, assess and even predict human behavior”, the press release states.

DayOne, the Basel-based startup accelerator for the life sciences sector, is a partner of both EvokAI and Advancience. DayOne and Basel Area Business & Innovation, the investment and innovation promotion agency, awarded Advancience one of the three startup spots for its DayOne Accelerator program at Technologiepark Basel in 2019, supporting it with a grant of 70,000 Swiss francs in the process.

Learn what it’s like to work in Switzerland, what permits you need as a foreign worker and how to find work here. Check out our working in Switzerland page for more info.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.